Mildronate

Not to be confused with Medronate, a bisphosphonate that forms a complex with radioactive technetium to be used as a radiopharmaceutical.

Mildronate is an antischemic agent of a metabolic action^[1] (cardioprotector) produced by Grindex in Latvia. The active substance is trimethylhydrazinium propionate dihydrate. ^[2][3]

Mechanism of action

Mildronate is a fatty acid oxidation inhibitor.^[4]

Indications

• Cardiovascular diseases: chronic coronary heart disease, stable angina pectoris,chronic heart failure, functional cardiovascular disturbances,cardiomyopathy.
• Acute and chronic ischemic cerebrovascular disturbances.
• Mildronate is used also in the cases of decreased performance, physical and psychoemotional overload, and during recovery process.^[5]

Forms

• 250 mg capsules N60
• 500 mg capsules N60
• Injection 10% 5 ml N10

Further reading

• Mildronate improves peripheral circulation in patients with chronic heart failure: results of a clinical trial (the first report); Vilnis Dzerve,*, Dace Matisone, Indulis Kukulis, Janina Romanova,Lilita Putane, Virginija Grabauskiene˙, Ilze Skarda, Dace Berzina, Jurgis Strautmanis ; http://www.seminarsincardiology.com/pdf/Seminars-2005-11-2-56-64.pdf
• . PMID 21420440. 
• Dambrova, M; Liepinsh, E; Kalvinsh, I (2002). "Mildronate Cardioprotective Action through Carnitine-Lowering Effect". Trends in Cardiovascular Medicine 12 (6): 275–9. doi:10.1016/S1050-1738(02)00175-5. PMID 12242052. 
• Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial ; http://www.grindeks.lv/mce/uploads/mici.pdf

References

1. ^ Leading pharmaceutical company in the Baltic States; http://www.grindeks.lv/en/products/prescription-medicine/grindeks-brand-products/mildronate
2. ^ Dambrova, M; Liepinsh, E; Kalvinsh, I (2002). "Mildronate Cardioprotective Action through Carnitine-Lowering Effect". Trends in Cardiovascular Medicine 12 (6): 275–9. doi:10.1016/S1050-1738(02)00175-5. PMID 12242052. 
3. ^ Dambrova, M; Liepinsh, E; Kalvinsh, I (2002). "Mildronate: Cardioprotective action through carnitine-lowering effect". Trends in cardiovascular medicine 12 (6): 275–9. doi:10.1016/S1050-1738(02)00175-5. PMID 12242052. 
4. ^ Dambrova, M; Liepinsh, E; Kalvinsh, I (2002). "Mildronate Cardioprotective Action through Carnitine-Lowering Effect". Trends in Cardiovascular Medicine 12 (6): 275–9. doi:10.1016/S1050-1738(02)00175-5. PMID 12242052. 
5. ^ http://www.grindeks.lv/en/products/prescription-medicine/grindeks-brand-products/mildronate/mildronate-250-mg-capsules-n60